Who
Alexander O. Schuth
COFO and Secretary
Company insider
Files Form 4 as: COFO and Secretary, Denali Therapeutics.
In numbers
- Trades disclosed
- 195
- Buys
- 0
- Sells
- 75
- Bought
- $0
- Sold
- $19.0M
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 26 Feb 2018
- Last trade
- 1 Sep 2026
- Last filed
- 3 Sep 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 1 Sep 2026filed 3 Sep 2026 | DNLI Denali TherapeuticsBiotechnology | SEC FORM 4 Sold | $65K2,768 at $23.44 | filing |
| 1 Sep 2026filed 3 Sep 2026 | DNLI Denali TherapeuticsBiotechnology | SEC FORM 4 Sold | $65K2,768 at $23.44 | filing |
| 11 Aug 2026filed 13 Aug 2026 | DNLI Denali TherapeuticsBiotechnology | SEC FORM 4 Sold | $72K2,857 at $25.07 | filing |
| 11 Aug 2026filed 13 Aug 2026 | DNLI Denali TherapeuticsBiotechnology | SEC FORM 4 Sold | $72K2,857 at $25.07 | filing |
| 6 Jan 2026filed 8 Jan 2026 | DNLI Denali TherapeuticsBiotechnology | SEC FORM 4 Sold | $284K17,218 at $16.50 | filing |
| 6 Jan 2026filed 8 Jan 2026 | DNLI Denali TherapeuticsBiotechnology | SEC FORM 4 Sold | $284K17,218 at $16.50 | filing |
| 3 Jan 2026filed 5 Jan 2026 | DNLI Denali TherapeuticsBiotechnology | SEC FORM 4 Code A | —57,700 at $0.00 | filing |
| 3 Jan 2026filed 5 Jan 2026 | DNLI Denali Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —173,100 at $0.00 | filing |
| 3 Jan 2026filed 5 Jan 2026 | DNLI Denali Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —173,100 at $0.00 | filing |
| 3 Jan 2026filed 5 Jan 2026 | DNLI Denali TherapeuticsBiotechnology | SEC FORM 4 Code A | —57,700 at $0.00 | filing |
| 12 Aug 2025filed 14 Aug 2025 | DNLI Denali TherapeuticsBiotechnology | SEC FORM 4 Sold | $40K2,937 at $13.58 | filing |
| 7 Jan 2025filed 8 Jan 2025 | DNLI Denali TherapeuticsBiotechnology | SEC FORM 4 Sold | $60K2,907 at $20.81 | filing |
| 6 Jan 2025filed 8 Jan 2025 | DNLI Denali TherapeuticsBiotechnology | SEC FORM 4 Sold | $248K12,255 at $20.22 | filing |
| 3 Jan 2025filed 7 Jan 2025 | DNLI Denali Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —162,540 at $0.00 | filing |
| 3 Jan 2025filed 7 Jan 2025 | DNLI Denali TherapeuticsBiotechnology | SEC FORM 4 Code A | —54,180 at $0.00 | filing |
| 27 Dec 2024filed 31 Dec 2024 | DNLI Denali Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —6,708 at $0.00 | filing |
| 27 Dec 2024filed 31 Dec 2024 | DNLI Denali TherapeuticsBiotechnology | SEC FORM 4 Code M | $35K6,708 at $5.28 | filing |
| 22 Nov 2024filed 26 Nov 2024 | DNLI Denali Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —20,516 at $0.00 | filing |
| 22 Nov 2024filed 26 Nov 2024 | DNLI Denali TherapeuticsBiotechnology | SEC FORM 4 Code M | $14K20,516 at $0.68 | filing |
| 7 Nov 2024filed 12 Nov 2024 | DNLI Denali Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —15,558 at $0.00 | filing |
News
Denali Therapeutics (NASDAQ:DNLI) vs. Century Therapeutics (NASDAQ:IPSC) Head-To-Head ContrastDNLI · themarketsdaily.com · 19 Oct 2026Denali Therapeutics (NASDAQ:DNLI) and Absci (NASDAQ:ABSI) Head to Head ComparisonDNLI · tickerreport.com · 11 Oct 2026
0 headlines in the last 90 days name Alexander O. Schuth; 2 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.